![[Translate to English:] Dr. Hans Riegel-Stiftung: Förderung Kinderherzen Stiftung Bonn](/fileadmin/_processed_/a/c/csm_Freya_Schaukel_6521_Picture_Moments_Fotografie_Narbe_bearbeitet_dc99c1ffa0.jpg "[Translate to English:] Dr. Hans Riegel-Stiftung: Förderung Kinderherzen Stiftung Bonn")
First Meta Study About Tachycardia in Newborns
Cardiac arrhythmia can already occur in unborn children in the womb and this can lead to tachycardia. Tachycardia can be harmful to babies in the womb because the rapid heartbeat prevents the child's blood from correctly being pumped through the body. Tachycardia in unborn children is treated by the mother taking medication, which eventually reaches the child through the placenta and the umbilical cord. So far, no large clinical studies have been carried out to compare the effectiveness of the different medicines or medicine combinations with one another.
The Dr. Hans Riegel Foundation is funding a first fundamental study in this subject area. For the first time, different medicines and medicine combinations can be compared in terms of effectiveness and safety based on a large amount of data. Accordingly, the aim is to know exactly which medicine is the optimum therapy in which situation.
The funding will run from 2019 to 2022.
Dr. Hans Riegel-Stiftung
Projektleiter Dr. Henning Hues
Am Neutor 3
53113 Bonn
0228-22744721
henning.hues@hans-riegel-stiftung.com
